The Brand Name LEVOPA Has Generic Salt :: Levodopa 

LEVOPA  Is From Company Wallace Priced :: Rs. 35.3

LEVOPA have Levodopa is comes under Sub class Drugs for Neurodegenerative Disorders of  Main Class Nervous System

Main Medicine Class:: Nervous System  Sub Medicine Class :: Drugs for Neurodegenerative Disorders 

Indications for Drugs ::

Parkinson’s disease and ‘end of dose’ motor fluctuations not controlled by levodopa/dopa decarboxylase inhibitor combinations.

Drug Dose ::

Adult: PO Per tab contains levodopa and carbidopa in a ratio of 4:1 w/ entacapone 200 mg. Initial: 1 tab/day. Titrate dose according to patient’s response. Recommended to take only 1 tab per dose administration. Max: 8 tabs/day.

Contraindication ::

Hypersensitivity. Narrow angle glaucoma. Should not be used in patients with suspicious, undiagnosed skin lesions or a history ot melanoma.

Drug Precautions ::

Periodic monitoring of hepatic, renal, haematopoietic and CV functions in patients on prolonged therapy. Monitor for changes in IOP in patients with chronic wide-angle glaucoma. Caution when used in patients with biliary obstruction. Caution when interpreting plasma and urine levels of catecholamines and their metabolites. Withdrawal should be gradual.

Drug Side Effects ::

Diarrhoea, nausea, vomiting, hypotension, hallucinations, hyperpyrexia and confusion. Fibrotic complications. Dark colour (red, brown or black) may appear in bodily secretions such as sweat, saliva and urine. Possible increase in dyskinesia. Chest pain, asthenia, cardiac irregularities, angioedema, urticaria, pruritus, back pain, shoulder pain and muscle cramps. Potentially Fatal: Rhabdomyolysis.

Pregnancy category ::

3

Drug Mode of Action ::  

Levodopa is the metabolic precurosor of dopamine, it crosses the blood-brain barrier and is converted to dopamine in the brain. Carbidopa increases the amount of levodopa that is transported into the CNS by inhibiting the decarboxylation of peripheral levodopa. Entacapone is a selective inhibitor of catechol-o-methyltransferase. Given concurrently, entacapone results in greater and more substained plasma levels of levodopa, leading to greater control of parkinsonism symptoms.

Drug Interactions ::

Increased risk of postural hypotension when used concurrently with hypotensive drugs. Severe orthostatic hypotension may result from concurrent usage with MAOIs. Dopamine D2 receptor antagonists, phenytoin or papaverine may reduce the efficacy of levodopa. Iron salts may reduce the bioavailability. Concurrent usage with drugs that interfere with biliary excretion may lead to increased plasma levels of entacapone. May depress prolactin secretion and increase growth hormone levels.